Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mult Scler Relat Disord. 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30.
Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population.
Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe.
A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms.
The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.
鉴于多发性硬化症(MS)在伊朗的高患病率和 COVID-19 的流行,对伊朗 MS 患者中的 COVID-19 进行了一项多中心研究,以解决该人群的担忧。
2020 年 7 月至 2021 年 3 月期间,通过在线注册系统收集伊朗九个省份的 MS 合并 COVID-19 患者的数据。COVID-19 症状中,呼吸困难、精神状态改变或导致住院的症状被认为是严重的。
共确定了 397 名符合条件的患者。此外,310 名(78%)为女性。平均年龄为 36.5 ± 9.5 岁。294 名(74%)患者为复发缓解型。另外,有 4 名患者(1%)因 COVID-19 感染而死亡。住院患者的平均住院时间为 9(± 5.3)天。111 名(28%)患者在发生 COVID-19 后进行了 MRI 检查。这些病例中有 27 例(24%)出现 MRI 改变。26 名(6%)患者改变了 MS 药物。过去三个月使用类固醇(OR:2.43,95%CI:1.003-5.88)(p 值:0.049)和抗 CD20s(OR:4.03,95%CI:2.41-6.68)(p 值<0.001)与 COVID-19 严重症状显著相关。
MS 患者 COVID-19 死亡率(1%)低于伊朗大流行的总体死亡率(3%)。过去三个月内使用类固醇的患者可能有更高的风险出现更严重的 COVID-19 症状。关于抗 CD20s 对 COVID-19 严重程度的影响仍存在疑问。